GoHealthcare Practice Solutions | Knowledge Center

GoHealthcare MSK Specialty Procedure Library™ | Ambulatory Surgery Center Operations

Medical Device Coverage

FDA Regulatory Pathways, Medicare and Commercial Coverage Determinations, Investigational Device Status, and Emerging Technology Access

A coverage-focused guide separating FDA authorization, Medicare coverage, commercial medical policy, investigational-device status, evidence requirements, coding, payment pathways, and patient-specific medical necessity.

Request HelpExplore the Guide

Publication and Use Information. This page is an educational and operational reference. It is not medical, legal, compliance, coding, or reimbursement advice and does not replace independent clinical judgment or verification of the payer, regulatory, coding, and payment requirements in effect for the specific patient and date of service. Authorization does not guarantee coverage or payment.

Up to 98%prior authorization approval rate reported in supported workflows

Operational performance depends on disciplined documentation and payer alignment.

GoHealthcare supports specialty practices and ASCs with prior authorization, utilization management, patient access, coding, revenue-cycle operations, compliance, and workflow optimization.

Review GoHealthcare case studies

Company-reported results vary by payer, patient population, clinical documentation, case mix, workflow design, and client execution.

Explore the Complete Guide

Use the links below to move directly to each section.

Guide Sections 1-8

1. Overview
2. Evidence at a Glance
3. FDA Regulatory Pathways
4. How Coverage Determinations Are Made
5. Applying Device Coverage to the Individual Patient
6. Non-Coverage: Investigational, Experimental, and Excluded Devices
7. Evidence Requirements and Coverage with Evidence Development
8. Documentation Supporting Device Coverage

Guide Sections 9-16

9. Diagnostic and Evidentiary Support
10. Medical Necessity for Devices
11. Medicare Device Coverage and the Emerging Technology Pathways
12. Commercial Device Coverage Comparison
13. Device Coverage Verification Workflow
14. Common Device Coverage Denials
15. Appeals, LCD Reconsideration, and NCD Requests
16. Coding and Billing Overview

Guide Sections 17-24

17. Coding for New and Emerging Device Technology
18. Device HCPCS Assignment and Coverage Timing
19. Diagnosis Documentation for Device Coverage
20. Modifiers, Beneficiary Notice, and Clinical Trial Reporting
21. Device Coverage Verification Checklist
22. Coverage Pathway Comparison
23. GoHealthcare Clinical Insights
24. GoHealthcare Leadership Perspective

Guide Sections 25-32

25. GoHealthcare Case Study
26. GoHealthcare Best Practices
27. Common Mistakes
28. Pearls and Pitfalls
29. Frequently Asked Questions
30. Key Takeaways
31. Future Outlook
32. References

Guide Sections 33-38

33. Reading Recommendations
34. Related GoHealthcare Resources
35. Recommended Downloads
36. Visual Recommendations
37. Educational Disclaimer

01

Overview

The single most consequential misconception in medical device operations is that FDA authorization means a device is covered. It does not, and the gap between the two is wide enough that the medical device industry has a name for it. A device can be lawfully marketed for years, be in routine clinical use, be the standard of care in the judgment of the treating specialty, and still be denied by every payer a practice bills. FDA answers whether a device may be sold. Coverage answers whether anyone will pay for it. These are separate determinations made by separate agencies under separate standards on separate timelines.

For a musculoskeletal ambulatory surgery center, that gap is expensive in a specific way. The facility acquires the implant before it knows the coverage outcome, opens it in the operating room, and cannot return it. Where the coverage answer turns out to be no, the loss is realized immediately and completely. Guide B04-03 addressed the authorization and payment mechanics of implants. This guide addresses the question that logically precedes them: is this device covered at all, by this payer, for this indication, in this patient?

Why this guide is unusually time-sensitive

Medicare's approach to covering new device technology changed materially in 2026, and the change is not yet complete. On April 23, 2026, CMS and the FDA jointly announced the Regulatory Alignment for Predictable and Immediate Device pathway, known as RAPID, intended to synchronize the national coverage determination process with FDA market authorization for certain Breakthrough Devices. CMS simultaneously paused the Transitional Coverage for Emerging Technologies pathway for new candidates. Separately, in the FY 2027 Inpatient Prospective Payment System proposed rule published April 14, 2026, CMS proposed to repeal the alternative pathway that has allowed Breakthrough Devices to qualify for New Technology Add-on Payment and for outpatient device pass-through payment without demonstrating substantial clinical improvement.

Status of the policies described in this guide, as of the publication date

RAPID is announced but not yet effective. A proposed procedural notice is to be published in the Federal Register with a 60-day comment period, and the pathway becomes effective only upon publication of a final notice. Nothing in this guide should be read as describing an operative pathway.

The pass-through alternative pathway repeal is proposed, not final. Comments closed June 9, 2026, and final IPPS policies were expected on or around August 1, 2026 - shortly after this guide's publication date. If finalized as proposed, all OPPS device pass-through applications received on or after October 1, 2026 would need to demonstrate substantial clinical improvement. Verify the outcome before relying on anything in this guide regarding pass-through eligibility.

TCET is paused for new candidates, not repealed. Devices already in the pathway and organizations with pending or planned applications should assess their position directly with CMS.

For an ASC or a musculoskeletal practice, the practical consequence of all three developments points the same direction: coverage for genuinely new device technology is becoming faster in principle and harder to qualify for in practice. Facilities should expect a narrower set of devices to receive expedited or separate payment treatment, and should expect that set to be defined by demonstrated clinical improvement rather than by regulatory designation alone.

Back to guide navigation

02

Evidence at a Glance

Domain	Current position (2026)
Relationship between FDA and coverage	Independent. FDA authorization establishes that a device may be lawfully marketed. It does not establish Medicare or commercial coverage, does not establish medical necessity for an individual patient, and does not establish separate payment.
Medicare national coverage	National Coverage Determinations bind all contractors nationally. Where no NCD exists, coverage is determined by the Medicare Administrative Contractor through Local Coverage Determinations and Local Coverage Articles, or case by case under the reasonable and necessary standard.
Coverage with Evidence Development	A mechanism by which CMS covers an item or service only when furnished in the context of approved clinical study or registry participation, used where evidence is promising but incomplete.
RAPID coverage pathway	Announced April 23, 2026 by CMS and FDA for certain Class II and Class III FDA-designated Breakthrough Devices. Eligibility requires participation in an investigational device exemption study including Medicare beneficiaries with agreed-upon clinical outcomes. CMS would issue a proposed NCD the same day as FDA market authorization. Not yet effective; proposed procedural notice and 60-day comment period pending.
Transitional Coverage for Emerging Technologies	Finalized August 2024 for up to five Breakthrough Devices per year, using the NCD and Coverage with Evidence Development processes. Paused for new candidates as CMS focuses on RAPID implementation.
Breakthrough Device designation	An FDA program under section 515B of the Federal Food, Drug, and Cosmetic Act for devices addressing life-threatening or irreversibly debilitating conditions that meet at least one of four additional criteria. FDA must decide a designation request within 60 calendar days. Designation is a regulatory status, not a coverage status.
Pass-through and add-on alternative pathway	CMS proposed on April 14, 2026 to repeal the alternative pathway permitting Breakthrough Devices to qualify without demonstrating substantial clinical improvement. If finalized, OPPS device pass-through applications received on or after October 1, 2026 would need to demonstrate substantial clinical improvement. Proposed, not final.
Investigational device exemption	Medicare may cover a Category B device, which FDA has determined is non-experimental or investigational. A Category A device, which is experimental, is not covered, although routine costs of care in a qualifying study may be.
Commercial coverage	Independent of Medicare. Commercial and vendor policies frequently classify devices as investigational or experimental where Medicare covers them, and the divergence is widest for newer musculoskeletal device categories.
Coding lag	A device may be covered with no specific HCPCS code, or coded with no coverage. Category III CPT® codes and unclassified device codes frequently mark the interval between clinical adoption and coverage.
Practical operating rule	Verify coverage for the specific device, the specific indication, and the specific payer before the case is scheduled. FDA status, clinical consensus, and prior payment history are each insufficient substitutes.

Back to guide navigation

03

FDA Regulatory Pathways

Understanding the FDA pathway a device took matters operationally, because it shapes what evidence exists, what the labeled indication says, how narrow that indication is, and what a payer is likely to make of it. It does not, however, determine coverage.

Device classification

Class	Risk level	Typical pathway	Musculoskeletal examples
Class I	Low	Most are exempt from premarket notification.	Basic surgical instruments and many supplies.
Class II	Moderate	Premarket notification (510(k)) demonstrating substantial equivalence to a legally marketed predicate device.	Many fixation devices, instrumentation systems, and a substantial share of orthopedic implants.
Class III	High	Premarket approval, requiring valid scientific evidence of safety and effectiveness.	Spinal cord stimulation systems, implantable drug infusion pumps, disc arthroplasty devices.

The pathways

Pathway	What it establishes	Coverage implication
510(k) premarket notification	That the device is substantially equivalent to a legally marketed predicate device.	Substantial equivalence is not a demonstration of clinical benefit. Payers frequently observe this, and a 510(k) device entering a category where the payer expects outcome evidence is a common investigational determination.
Premarket approval	Reasonable assurance of safety and effectiveness based on valid scientific evidence, for the specific approved indication.	The strongest FDA foundation for a coverage argument, but the approved indication is frequently narrower than clinical use. Read the indication, not the device name.
De Novo classification	A new device type with no predicate is classified into Class I or II with special controls.	Creates a new regulatory category. Payer policy frequently has not yet addressed the category, producing coverage uncertainty rather than coverage.
Humanitarian device exemption	Authorization for a humanitarian use device intended for a condition affecting a small patient population, on a demonstration of probable benefit rather than effectiveness.	Coverage posture varies and is frequently restrictive. Do not assume parity with cleared or approved devices.
Investigational device exemption	Permission to use an investigational device in a clinical study.	Coverage depends on the Category A or Category B determination, addressed in Section 6.
Breakthrough Device designation	That the device addresses a life-threatening or irreversibly debilitating condition and meets at least one of four further criteria: it represents breakthrough technology; no approved or cleared alternatives exist; it offers significant advantages over existing alternatives; or its availability is in patients' best interest.	A designation, not an authorization and not a coverage decision. It confers eligibility for certain expedited pathways, and CMS has proposed to narrow the payment advantages historically attached to it.

GoHealthcare Clinical Insight: read the indication, not the device

The most common source of avoidable device denials in musculoskeletal practice is a mismatch between the FDA-authorized indication and the clinical use, in situations where nobody involved understood there was a mismatch.

Authorized indications are frequently narrower than the device's clinical reputation. They may specify an anatomic level or range, a diagnosis, a prior-treatment requirement, a number of levels, a patient age range, or a combination. A device widely described as approved for a condition may be approved only for a subset of it.

The discipline is to obtain and read the actual indications for use statement for each system in regular use, record it in the facility's device reference, and compare it to the intended clinical application at scheduling. Where use falls outside it, that is not necessarily wrong - but it is off-label, and it must be addressed affirmatively in the authorization request rather than discovered in the denial.

Back to guide navigation

04

How Coverage Determinations Are Made

Medicare

Level	Instrument	Scope and effect
National	National Coverage Determination	Binds all Medicare Administrative Contractors nationally. May grant coverage, deny coverage, or grant coverage subject to conditions including Coverage with Evidence Development.
National	Coverage with Evidence Development	Coverage conditioned on the beneficiary's participation in an approved clinical study or registry. Used where evidence is promising but incomplete.
Local	Local Coverage Determination	Contractor-specific coverage policy where no NCD addresses the item or service. Different contractors may reach different conclusions on the same device.
Local	Local Coverage Article	Contractor-issued companion guidance, frequently carrying the coding and billing detail and the covered diagnosis lists that operationalize an LCD.
Case by case	Contractor discretion under the reasonable and necessary standard	Where neither an NCD nor an LCD addresses the device. The least predictable posture and the one most dependent on documentation quality.

A practical implication of the local level deserves emphasis. Because Local Coverage Determinations are contractor-specific, a device may be covered in one jurisdiction and not another. Multi-state ASC organizations cannot maintain a single national coverage matrix for Medicare. This surprises organizations expanding across contractor boundaries more often than any other coverage fact.

Commercial

Commercial coverage is determined by the plan's medical policy or by the criteria of the vendor to which review is delegated. Commercial policy is not bound by Medicare determinations. Plans regularly classify as investigational devices that Medicare covers, and the divergence is widest precisely where it matters most in musculoskeletal practice: newer neuromodulation categories, sacroiliac joint fusion approaches, disc arthroplasty at multiple levels, interspinous devices, and basivertebral and other ablation technologies.

Medicare Advantage occupies a middle position. Plans must apply Traditional Medicare coverage criteria where such criteria exist, and may apply internal criteria only where Traditional Medicare criteria are absent or incomplete. Where an NCD or applicable LCD covers a device, citing it explicitly in the request is effective and is the strongest argument available.

Back to guide navigation

05

Applying Device Coverage to the Individual Patient

A device being covered in general does not mean it is covered for this patient. Coverage policies operate through criteria, and the criteria are applied individually.

Criterion type	What it requires	Where it fails
Diagnosis within the covered indication	The patient's diagnosis must fall within the indication the policy covers, at the specificity the policy requires.	A clinically accurate diagnosis outside the policy's covered list. Accuracy and coverage are different questions.
Anatomic scope	Level, region, joint, or nerve target within the covered scope, which is frequently narrower than the device's general application.	Multi-level use where the policy covers single-level; a target outside the covered anatomic range.

Criterion type	What it requires	Where it fails
Prior treatment	Documented failure of specified conservative or less invasive therapy over a specified duration.	Narrative conservative care without modalities, dates, adherence, and outcome.
Diagnostic confirmation	Imaging, diagnostic block response, electrodiagnostic study, or other confirmation the policy specifies.	Confirmation obtained but not documented against the policy's stated threshold.
Trial requirement	For neuromodulation, a successful trial meeting a defined response threshold.	Trial characterized as successful without measurement.
Psychological or behavioral evaluation	Required by several neuromodulation policies before permanent implantation.	Evaluation performed but not obtained by the authorization team, or performed after the request was submitted.
Exclusion criteria	Absence of conditions the policy identifies as disqualifying.	An exclusion present in the record and unaddressed. Reviewers find these; requests are stronger when the exclusion is addressed rather than left to be discovered.
Site of service	Appropriateness of the ASC for this device and patient.	Addressed in Guide B04-01, Section 4.

Back to guide navigation

06

Non-Coverage: Investigational, Experimental, and Excluded Devices

Investigational device exemption categories

Where a device is used under an FDA investigational device exemption, Medicare coverage turns on the category FDA assigns.

Category	FDA determination	Medicare treatment
Category A	Experimental. Absolute risk of the device type has not been established, and initial questions of safety and effectiveness remain unresolved.	The device itself is not covered. Routine costs of care furnished in a qualifying study may be covered, subject to applicable requirements.
Category B	Non-experimental or investigational. The device type is known to be safe and effective, or the incremental risk is the principal question.	The device may be covered, subject to the study meeting applicable requirements and the contractor's determination.

The operational consequences differ substantially, and the determination must be confirmed before the case rather than assumed from the study's existence. Facilities participating in device trials should hold the category determination, the study approval documentation, and the contractor's requirements in the facility record, not rely on the sponsor's representation.

Commercial investigational determinations

Commercial payers apply their own investigational and experimental definitions, which are contractual rather than regulatory. A device may be FDA-approved, Medicare-covered, and still designated investigational by a commercial plan. This is a policy position rather than a documentation gap, and it has an important practical consequence: clinical appeals against categorical investigational exclusions rarely succeed. The determination must be made before scheduling.

Other exclusion bases

• Statutory exclusion, such as devices used for purposes Medicare does not cover as a category.
• Benefit category determination - the threshold question of whether the item falls within any Medicare benefit category at all. A device outside every benefit category cannot be covered regardless of evidence.
• Non-covered indication, where the device is covered for some uses and not the one requested.

• Frequency or quantity limitation, where the policy limits units, levels, or repeat procedures.
• Absence from the ASC Covered Procedures List for the associated procedure, which forecloses Medicare facility payment irrespective of device coverage.
• Plan benefit exclusion or exhausted benefit, which is independent of medical policy.

Back to guide navigation

07

Evidence Requirements and Coverage with Evidence Development

Coverage determinations turn on evidence, and understanding what payers are looking for changes how a coverage argument should be constructed. The recurring standard in Medicare policy is whether the item is reasonable and necessary; in commercial policy it is typically whether the device has been demonstrated to improve net health outcomes compared with established alternatives.

Evidence attribute	What payers look for	Why device evidence often falls short
Study design	Randomized controlled trials with appropriate comparators; blinded or sham-controlled designs where feasible.	Device trials are frequently single-arm, unblinded, or compared against non-operative care rather than an active surgical alternative.
Outcomes measured	Clinically meaningful outcomes - function, return to activity, durable pain reduction, reoperation - rather than surrogate or technical endpoints.	Radiographic fusion, device survivorship, and technical success are frequently reported in place of patient-centered outcomes.
Duration of follow-up	Follow-up sufficient to establish durability, which for implants generally means years.	Regulatory authorization may rest on shorter follow-up than payers require for coverage.
Population studied	A population representative of the patients for whom coverage is sought, including Medicare beneficiaries where relevant.	Trials frequently exclude older patients and those with the comorbidity burden typical of the Medicare population.
Comparative effectiveness	Demonstration of benefit relative to established alternatives, not merely relative to no treatment.	Substantial equivalence under 510(k) establishes similarity to a predicate, not superiority or equivalence in outcome.
Independence	Evidence not exclusively sponsor-generated.	Early device literature is frequently sponsor-funded and sponsor-authored, which payers discount.

Coverage with Evidence Development

Where evidence is promising but incomplete, CMS may cover an item only when furnished to a beneficiary enrolled in an approved clinical study or registry. This is Coverage with Evidence Development, and it creates specific and frequently underestimated operational obligations for the facility.

• The patient must be enrolled in a qualifying study or registry, and enrollment must be documented before the service.
• Study or registry participation carries data submission obligations that continue after the episode and require assigned responsibility.
• Claims must be reported with the applicable clinical trial billing elements, addressed in Section 20.
• The facility must be able to demonstrate, on audit, that the coverage condition was satisfied for each case billed.

• Coverage outside the study condition is not coverage. A patient not enrolled is not covered, regardless of clinical appropriateness.

Back to guide navigation

08

Documentation Supporting Device Coverage

• Device identified specifically: manufacturer, system, model, and where relevant components
• The FDA-authorized indication for the device, and confirmation that the clinical use falls within it, or affirmative documentation of off-label use with justification
• The patient's diagnosis at the specificity the coverage policy requires, with anatomic level, region, and laterality
• Each element of the applicable coverage policy addressed, in the policy's own terms and order
• Conservative and prior treatment history with modalities, dates, duration, adherence, and outcome
• Diagnostic confirmation the policy requires, documented against the policy's stated threshold
• Trial documentation with measured response where a trial is a prerequisite
• Psychological or behavioral evaluation where the policy requires it, obtained before submission
• Exclusion criteria affirmatively addressed rather than left unmentioned

• The applicable NCD, LCD, Local Coverage Article, or commercial policy identified by number and version, with the version in effect on the date of service
• Where Coverage with Evidence Development applies, study or registry enrollment documented before the service
• Where an investigational device exemption applies, the Category A or Category B determination and study approval documentation
• Advance Beneficiary Notice of Non-coverage where non-coverage is anticipated, with the correct modifier pathway identified

Back to guide navigation

09

Diagnostic and Evidentiary Support

Support type	Coverage function	Common gap
Advanced imaging	Establishes the pathology the device treats, at the level and side of intended use.	Report submitted without treating physician correlation to the clinical presentation.
Diagnostic block response	Required by several policies for sacroiliac joint, facet-mediated, and selected neuropathic indications, frequently with a defined percentage response threshold and sometimes more than one block.	Response documented qualitatively rather than against the policy's numeric threshold, or a single block where the policy requires confirmatory blocks.
Electrodiagnostic study	Supports neuropathic indications for selected neuromodulation applications.	Obtained but not submitted, or performed outside the policy's recency window.
Functional instruments	Establish baseline impairment and response to prior treatment.	Captured at one point only, so no trajectory is demonstrable.
Trial response measurement	The determinative evidence for permanent neuromodulation implantation.	Trial documented as successful without measurement against the threshold. The most consequential single gap in device coverage documentation.
Psychological evaluation	Required before permanent implantation under several neuromodulation policies.	Performed by a clinician outside the practice and never obtained by the authorization team.

Back to guide navigation

10

Medical Necessity for Devices

Device medical necessity has a structure distinct from procedure medical necessity, and submissions that address only the procedure leave the device determination to be made without argument. Four propositions must be established.

Proposition	What establishes it
The condition warrants intervention	Diagnosis, symptom duration, functional impairment, and documented failure of conservative care.
A device-based intervention is appropriate	Why a device is indicated rather than continued conservative management or a non-device surgical alternative.
This device category is appropriate	Why this category - stimulation rather than ablation, fusion rather than arthroplasty, and so on - addressing the categorical alternatives the policy contemplates.
This specific device is appropriate for this patient	Anatomic fit, anticipated imaging needs addressed by conditional labeling, revision compatibility with existing hardware, trial response to a specific modality, or another patient-specific attribute. Surgeon familiarity is clinically legitimate but is not a reviewable argument.

Where the honest answer to the fourth proposition is that several comparable systems would serve, the stronger submission addresses the device at the category level and does not invite a device-specific challenge that does not need to be had.

Back to guide navigation

11

Medicare Device Coverage and the Emerging Technology Pathways

The coverage lag problem

The interval between FDA market authorization and a Medicare national coverage determination has historically run approximately a year or more. During that interval a device is lawfully marketed and clinically available but has no national coverage position, leaving coverage to contractor discretion, case-by-case determination, or nothing at all. Successive administrations have attempted to close this gap. The current architecture is the product of those attempts and is in active transition.

Pathway	Status	Mechanism	Scope
Standard NCD process	Operative.	CMS opens, decides, or reconsiders a national coverage determination through the established process with public comment.	Any item or service. The default and the fallback.
Local coverage	Operative.	Contractor-issued LCDs and Local Coverage Articles, with a reconsideration process available to interested parties.	Contractor jurisdiction only. Different contractors may differ.
Coverage with Evidence Development	Operative.	Coverage conditioned on approved study or registry participation.	Items with promising but incomplete evidence.
Parallel Review	Operative.	Concurrent FDA and CMS review, historically limited in the number of candidates.	Selected technologies.
Transitional Coverage for Emerging Technologies	Paused for new candidates.	Finalized August 2024. Used the NCD and CED processes with an evidence development plan, targeting a finalized NCD within six months of FDA market authorization.	Up to five FDA-designated Breakthrough Devices per year.

Pathway	Status	Mechanism	Scope
RAPID coverage pathway	Announced April 23, 2026; not yet effective. Proposed procedural notice and 60-day comment period pending; effective upon final notice.	CMS would issue a proposed NCD the same day the device receives FDA market authorization, triggering the statutory 30-day comment period, with a final NCD targeted within roughly 60 to 90 days. Does not confer automatic coverage.	Certain Class II and Class III FDA-designated Breakthrough Devices, with eligibility requiring an investigational device exemption study including Medicare beneficiaries and agreed-upon clinical outcomes.

What the 2026 realignment means for a musculoskeletal ASC

Two policy movements are running in opposite directions simultaneously, and the net effect is easy to misread.

• Coverage is being accelerated. RAPID would compress the interval between FDA authorization and national coverage from roughly a year to potentially two months, for devices that qualify.
• Separate payment is being tightened. The proposed repeal of the alternative pathway would require device pass-through applicants to demonstrate substantial clinical improvement, a criterion the Breakthrough designation previously exempted them from.

For an ASC the second matters more than the first. Pass-through is the mechanism by which a genuinely new implant is paid separately rather than absorbed into a packaged procedure rate. Narrowing eligibility means fewer new devices will receive separate payment, and more will arrive already packaged into rates set before the device existed.

The planning assumption for leadership should be that coverage for new device technology arrives faster but carries separate payment less often. That combination increases rather than decreases the importance of the implant margin modeling described in Guide B04-03, because it means more new technology will need to be absorbed at packaged rates.

Back to guide navigation

12

Commercial Device Coverage Comparison

Payer or vendor	Device coverage posture	Operational emphasis
eviCore healthcare	Delegated musculoskeletal, spine, and interventional pain criteria containing device-relevant requirements, particularly trial and conservative care prerequisites for neuromodulation.	Build the submission to the criteria in their own order. Trial measurement is the highest-yield element.
Carelon Medical Benefits Management	Clinical appropriateness guidelines addressing musculoskeletal, spine, joint, and pain management, with dated versions updated on a defined cycle.	The version in effect on the date of service governs. Verify current version each batch. Counsel review of the artificial intelligence use clause remains an open item.
Cohere Health	Episode-based authorization across musculoskeletal service lines.	Establish what the authorized episode covers with respect to devices.
Evolent	Delegated musculoskeletal management; device HCPCS codes associated with a delegated CPT® code are reviewed for medical necessity under the same delegation.	Program scope differs by plan contract and has moved between vendors at several plans.
TurningPoint Healthcare Solutions	Surgical and implantable device management programs with explicit device consideration and documentation sections in criteria, reviewing both professional and facility claims at some plans.	Device specification belongs in the original request. Post-service claim review means authorization is not the end of exposure.
UnitedHealthcare	Medical policies addressing specific device categories, plus facility reimbursement policy governing device and implant reporting.	Coverage policy and reimbursement policy are separate documents and both apply.

Payer or vendor	Device coverage posture	Operational emphasis
Aetna	Clinical Policy Bulletins addressing device categories specifically, applied literally.	Map the submission to the bulletin's enumerated criteria. Positions on newer musculoskeletal device categories are frequently restrictive.
Cigna Healthcare	Published coverage policies with delegated vendor review for selected programs.	Verify plan-reviewed versus vendor-reviewed before submission.
Humana	Medical coverage policies across commercial and Medicare Advantage lines.	For Medicare Advantage, cite the applicable NCD or LCD explicitly; plans must apply Traditional Medicare criteria where they exist.
Blue Cross Blue Shield plans	Independent licensees with materially different device policies by state and product.	Never generalize across Blue plans. BlueCard out-of-area members follow the home plan's medical policy.

Where Medicare and commercial coverage most often diverge

The following musculoskeletal device categories are, in our experience, the most frequent sources of divergence between Medicare and commercial coverage, and between one commercial payer and another. This list identifies where verification effort should be concentrated. It is not a statement of any payer's current position, all of which must be verified for the specific payer, product, and date of service.

• Peripheral nerve stimulation, where coverage positions vary widely by nerve target, by device, and by whether the system is temporary or permanent.
• Sacroiliac joint fusion, where approach and device type are treated differently across policies and diagnostic block requirements differ.
• Disc arthroplasty, particularly multi-level application and cervical versus lumbar.
• Interspinous and interlaminar devices.
• Basivertebral and other ablation technologies.
• Restorative and closed-loop neurostimulation modalities and specific waveforms.
• Bone graft substitutes and biologics, which frequently carry restrictive positions independent of the fusion procedure.
• Regenerative and orthobiologic products, where investigational determinations are common.
• Robotic and navigation assistance, where coverage of the enabling technology differs from coverage of the procedure.

Back to guide navigation

13

Device Coverage Verification Workflow

Stage	Actions	Failure if skipped
1. Device identification	Identify the specific device system and components intended, from the preference card and planned procedure.	Coverage verified for a category rather than the device actually used.
2. FDA status confirmation	Obtain the authorized indications for use statement and confirm the intended clinical use falls within it.	Undetected off-label use, denied for a reason nobody anticipated.
3. Benefit category and coverage determination	Determine whether an NCD, applicable LCD, Local Coverage Article, or commercial policy addresses the device, and identify it by number and version.	Coverage assumed from prior payment history, which is not a coverage determination.
4. Jurisdiction check	For Medicare, confirm the applicable contractor's position for the facility's jurisdiction.	A national assumption applied where local coverage governs and differs.
5. Criteria mapping	Map each policy criterion to the documentation that satisfies it, identifying gaps before submission.	Adverse determination on a criterion that was satisfiable but unaddressed.

Stage	Actions	Failure if skipped
6. Investigational and study status	Where applicable, confirm the IDE category, study approval, and any Coverage with Evidence Development condition, and document enrollment before the service.	A coverage condition unsatisfied at the time of service and unsatisfiable afterward.
7. Submission	Submit addressing the device explicitly, in the policy's own terms and order.	Device determination made without argument.
8. Determination capture	Capture device-level terms, limitations, and any partial determination into the facility record.	A partial determination recorded as an approval.
9. Financial confirmation	Confirm the device is reimbursed under the applicable contract and model the margin.	A covered device that is nonetheless unreimbursed under the contract.
10. Beneficiary notice	Where non-coverage is anticipated, execute the appropriate notice and identify the modifier pathway before the service.	Liability that cannot be transferred after the fact.
11. Coding and reporting	Report the device code, any clinical trial billing elements, and the associated procedure consistently.	Coverage established and payment lost on reporting.
12. Policy monitoring	Track policy version changes for the device categories the facility uses.	A device covered last quarter and not this quarter, discovered on remittance.

Back to guide navigation

14

Common Device Coverage Denials

Denial	Category	Root cause	Prevention
Device is investigational or experimental	Policy	Categorical policy position not identified before scheduling.	Pre-scheduling coverage determination. Clinical argument does not overcome categorical exclusion.
Use outside the FDA-authorized indication	Clinical	Indication statement never read; mismatch undetected.	Maintain authorized indications in the facility device reference; address off-label use affirmatively.
Diagnosis not within the covered indication	Administrative and clinical	Accurate diagnosis outside the policy's covered list.	Cross-reference diagnosis against the policy's covered list before submission.
Anatomic scope outside coverage	Clinical	Multi-level or off-target use where the policy covers a narrower scope.	Verify anatomic scope in the policy, not the device labeling alone.
Conservative care insufficient	Clinical	Narrative without modalities, dates, adherence, and outcome.	Structured prospective conservative care documentation.
Trial documentation insufficient	Clinical	Trial characterized as successful without measurement.	Measure and document trial response against the policy's threshold.
Required evaluation not obtained	Administrative	Psychological or specialist evaluation performed elsewhere and never collected.	Include required evaluations in the pre-service document set.
Coverage with Evidence Development condition unmet	Administrative	Enrollment not documented before the service.	Enrollment verified and documented pre-service; the condition cannot be cured afterward.
Local coverage differs from assumption	Administrative	National assumption applied in a jurisdiction with a differing LCD.	Jurisdiction-specific coverage matrix for multi-state organizations.

Denial	Category	Root cause	Prevention
Policy version changed	Administrative	Criteria verified once and carried forward.	Version tracking for the device categories in regular use.
Category A investigational device billed	Policy	Category determination assumed rather than confirmed.	Confirm IDE category and hold the documentation in the facility record.
Benefit category determination adverse	Policy	The threshold question of benefit category never asked.	For genuinely novel technology, confirm a benefit category exists before anything else.

Back to guide navigation

15

Appeals, LCD Reconsideration, and NCD Requests

Case-level appeal

Where an individual determination is adverse, the remedies are those described in Guide B04-01, Section 15. The classification discipline matters especially for device denials: a denial resting on a categorical policy position is not a documentation problem and rarely yields to a clinical appeal, while a denial resting on an unaddressed criterion frequently does.

Policy-level remedies

Where a coverage position is wrong at the policy level rather than misapplied at the case level, case-by-case appeals are the wrong instrument. Policy-level mechanisms exist and are under-used by provider organizations.

Mechanism	What it is	Practical considerations
LCD reconsideration	A formal request to a Medicare Administrative Contractor to revise or retire a Local Coverage Determination, available to interested parties.	Requires supporting evidence meeting the contractor's requirements. Specialty societies frequently lead these; individual practices can contribute clinical data and support.
NCD reconsideration request	A formal request that CMS reconsider an existing national coverage determination.	Evidence-intensive and lengthy. Generally a manufacturer or specialty society undertaking.
Comment on proposed determinations	Public comment on proposed NCDs, proposed LCDs, and proposed rules.	Low cost and genuinely influential, particularly where practices can supply operational and clinical experience the agency lacks.
Commercial policy reconsideration	Most plans and vendors maintain a process for submitting evidence supporting policy revision.	Slower than an appeal but addresses the recurring denial rather than the instance. Worth pursuing where a category denies repeatedly.
Specialty society engagement	Coordinated advocacy through the relevant professional organization.	The most effective route for most individual practices, and the one requiring the least institutional capacity.

GoHealthcare Prior Authorization Insight: know when to stop appealing

Facilities frequently spend more on appealing a categorical investigational determination than the claim is worth, and lose anyway. The distinguishing question is simple: is the payer saying this documentation is insufficient, or is the payer saying this device is not covered for anyone?

The first is worth appealing and frequently winnable. The second is a policy position. The correct response to the second is to stop scheduling the case against that payer until the policy changes, to pursue the policy-level remedies above, and to have the financial conversation with the patient in advance rather than after.

Tracking device denials by whether they are documentation-based or policy-based is the measurement that makes this distinction visible. Most facilities track neither.

Back to guide navigation

16

Coding and Billing Overview

Coverage and coding fail each other in both directions, and the failure mode is different in each case.

Situation	Consequence	Response
Covered device, no specific code	The device is payable in principle but there is no precise way to report it.	Report the unclassified device code where applicable, with documentation supporting the device furnished. Expect manual review.
Coded device, no coverage	A code exists and the device denies anyway.	The existence of a code is not a coverage determination. This is among the most persistent misconceptions in device billing.
Category III CPT® code	Frequently denied as investigational under payer policy rather than on documentation.	Determine coverage posture before scheduling. Category III assignment often signals a coverage question, not merely a coding one.
New technology with no code at all	Nothing to report.	Unlisted code with narrative and comparison code; extended lead time; confirm the payer's process before the case.

Back to guide navigation

17

Coding for New and Emerging Device Technology

Code type	Coverage significance
Category I CPT®	Established procedures with demonstrated clinical efficacy and widespread use. Coverage is still policy-dependent, but a Category I code generally signals the procedure has cleared the evidentiary threshold for code establishment.
Category III CPT®	Temporary codes for emerging technology, services, and procedures. Frequently associated with investigational determinations under payer policy. Assignment of a Category III code is often the operative signal that coverage must be verified before scheduling rather than assumed.
Unlisted CPT®	Used where no code describes the service. Requires narrative and a comparison code for most payers; unlisted codes are among the surgical procedures excluded from Medicare payment in the ASC. Lead time must be extended substantially.
HCPCS Level II C-codes	Describe devices for facility reporting and pass-through payment. Establishment of a device category code is a payment mechanism, not a coverage determination.
Unclassified device codes	Used where no specific device code exists. Expect manual review and prepare the supporting documentation in advance.

Code type	Coverage significance
Proprietary and administrative codes	Some payers maintain their own codes for specific devices or services. These are payer-specific and must be confirmed rather than inferred.

The coding lag is a structural feature rather than an administrative failure. Code sets update on fixed cycles; devices reach market continuously. A facility adopting new technology should expect a period in which coding is imprecise, payment is uncertain, and manual review is routine, and should plan the cash flow consequences accordingly.

Back to guide navigation

18

Device HCPCS Assignment and Coverage Timing

Timing question	What to verify
Does a device code exist?	Check the current HCPCS release and the quarterly update articles. New device category codes are established between annual releases.
Is the code payable in the ASC setting?	Verify the ASC payment indicator. Some device codes are payable only in the hospital outpatient setting, and some are ASC-specific.
Is there an active pass-through category?	Verify the category is active for the date of service. Pass-through runs at least two but not more than three years and expires on a knowable date.
What procedures may the device code be reported with?	The ASC code pair file governs. A device code outside its permitted pairing fails.
Has the descriptor changed?	Descriptors are revised between rules. A code carried forward from a prior year may no longer describe the device in use.
Does coverage exist independent of the code?	Always the separate question. Code establishment is a payment mechanism and says nothing about whether the payer covers the device.

Back to guide navigation

19

Diagnosis Documentation for Device Coverage

Issue	Requirement
Covered diagnosis list	Most device coverage policies and Local Coverage Articles enumerate covered diagnoses. A clinically accurate diagnosis outside the list will deny. Cross-reference before submission.
Specificity	Character-level specificity supporting the covered indication, including laterality and anatomic region where the code set provides them.
Level and region concordance	The diagnosis, the imaging, the examination, the device placement, and the procedure must all describe the same level and side.
Severity and chronicity	Where coverage depends on severity, duration, or failure of prior treatment, the diagnosis coding should reflect it rather than leaving it entirely to narrative.
Device status and complication codes	Presence of a device, mechanical complication, device-related infection, and displacement codes, where applicable to revision and replacement.
Clinical research encounters	Where a device is furnished in an approved clinical study, the applicable research encounter diagnosis reporting requirements apply in addition to the clinical diagnosis.

Back to guide navigation

20

Modifiers, Beneficiary Notice, and Clinical Trial Reporting

Element	Application
GA modifier	Waiver of liability statement on file. Applied where an Advance Beneficiary Notice of Non-coverage was issued because payment is expected to be denied as not reasonable and necessary. The mechanism by which financial liability is transferred to the beneficiary.
GX modifier	Notice of liability issued voluntarily. Applied where denial is expected under a statutory exclusion.
GY modifier	Item or service statutorily excluded or not a Medicare benefit.
GZ modifier	Item or service expected to be denied as not reasonable and necessary, where no Advance Beneficiary Notice was issued. Liability cannot be transferred to the beneficiary.
Clinical trial reporting	Services furnished in an approved clinical study carry specific reporting requirements, including designation of investigational versus routine services, the applicable research encounter diagnosis reporting, and the clinical trial identifier. Requirements differ between the professional and institutional claim formats. Confirm the current requirements with the contractor before the first case rather than after.
FB and FC	Device furnished without cost or with credit, as addressed in Guide B04-03.
Q modifiers for research services	Used to distinguish investigational clinical services from routine clinical services within an approved clinical research study. Application is specific and should be confirmed against current contractor guidance.

Beneficiary notice is a pre-service obligation

Where non-coverage of a device is anticipated, an Advance Beneficiary Notice of Non-coverage must be issued in advance of the service. Financial liability cannot be transferred to a Medicare beneficiary retroactively.

This is the point at which device coverage verification becomes a patient-facing obligation rather than a back-office one. A facility that learns of non-coverage after the implant is placed has both a write-off and a patient who was never given the opportunity to make an informed financial decision. The second is the more serious failure.

Commercial plans have their own advance notice and member liability rules, which differ from Medicare and from each other, and which are frequently constrained by contract terms and by federal and state balance billing protections. These should be recorded in the payer matrix alongside the coverage position.

Back to guide navigation

21

Device Coverage Verification Checklist

Before scheduling

• Specific device system and components identified
• FDA-authorized indications for use obtained and compared to the intended clinical application
• Off-label use identified where applicable and a justification approach determined
• Benefit category confirmed for genuinely novel technology
• Applicable NCD, LCD, Local Coverage Article, or commercial policy identified by number and version
• Contractor jurisdiction confirmed for Medicare cases
• Coverage posture confirmed for the specific indication, not the device generally
• Category III or unlisted code status identified, with the coverage implication assessed
• Investigational device exemption category confirmed where applicable
• Coverage with Evidence Development conditions identified where applicable

• Contract reimbursement basis for the device confirmed, separately from coverage

Before the case

• Each policy criterion mapped to supporting documentation, with gaps closed
• Trial documentation with measured response assembled where required
• Required evaluations obtained and in hand
• Study or registry enrollment documented where coverage is conditioned on it
• Device-level authorization determination captured, including limitations and partial determinations
• Advance Beneficiary Notice executed where non-coverage is anticipated, with the modifier pathway identified
• Patient financial discussion completed where liability may fall to the patient

At coding and billing

• Device code assigned and verified as payable in the ASC setting
• Code pair relationship verified
• Pass-through status confirmed active for the date of service where applicable
• Clinical trial reporting elements applied where applicable
• Modifier pathway applied consistently with the notice issued
• Diagnosis cross-referenced against the policy's covered list
• Denial reason captured as documentation-based or policy-based for aggregate analysis

Back to guide navigation

22

Coverage Pathway Comparison

Attribute	Standard NCD	Local coverage	TCET	RAPID (proposed)
Status	Operative	Operative	Paused for new candidates	Announced; not yet effective
Scope	Any item or service	Contractor jurisdiction	Up to five Breakthrough Devices per year	Certain Class II and III Breakthrough Devices
Eligibility	General	General	FDA Breakthrough designation and nomination	Breakthrough designation plus an IDE study including Medicare beneficiaries with agreed clinical outcomes
Timing anchor	CMS initiation or external request	Contractor initiation or reconsideration request	Targeted finalized NCD within roughly six months of FDA market authorization	Proposed NCD issued the same day as FDA market authorization
Expected interval to coverage	Historically a year or more	Variable	Approximately six months post-authorization	Potentially about two months post-authorization; final NCD targeted within roughly 60 to 90 days
Automatic coverage	No	No	No	No
Evidence development	CED where applied	Not typically	Evidence development plan with fit-for-purpose studies	Evidence generated for FDA review intended to support the coverage decision

Attribute	Standard NCD	Local coverage	TCET	RAPID (proposed)
Relevance to an ASC	The default pathway for most device categories	Where most musculoskeletal device coverage actually lives	Limited by volume; monitor rather than plan around	Monitor closely; the pathway most likely to shape access to new MSK technology

Back to guide navigation

23

GoHealthcare Clinical Insights

Maintain a device coverage matrix, separate from the procedure matrix

Device coverage does not follow procedure coverage, and organizations that maintain a single matrix consistently discover this the expensive way. The device matrix should record, for each device category the facility uses: the applicable policy by number and version, the covered indications, the anatomic scope, the prerequisites, the exclusions, the jurisdiction where relevant, the contract reimbursement basis, and the date last verified.

Hold the indications for use statements

Obtain and retain the authorized indications for use for every device system in regular use. This is a small, one-time effort that closes an entire denial category. Where use falls outside the indication, the facility then knows it at scheduling rather than at adjudication, and can make an informed decision.

Distinguish documentation denials from policy denials in the data

These require entirely different responses and are frequently aggregated into a single unhelpful category. Documentation denials are fixed by improving documentation. Policy denials are addressed by policy-level remedies, by contract negotiation, by patient financial counseling, or by not scheduling the case. A facility that cannot tell them apart will apply the wrong response to both.

Treat Category III codes as a coverage signal

When a service or device carries a Category III code, treat that as a prompt to verify coverage before scheduling rather than as a coding detail. The correlation between Category III assignment and investigational determination is high enough to be operationally useful.

Build the patient financial conversation into the pathway

Where a device is likely to be non-covered and the patient still wishes to proceed, that conversation must happen before the case, with the appropriate notice executed. This is both a compliance requirement and a patient-respect obligation. Facilities that handle it well experience fewer disputes and better patient relationships than those that discover the issue afterward.

Monitor policy versions for the categories you actually use

Monitoring all device policy is impractical. Monitoring the ten or fifteen categories a facility actually implants is entirely practical and captures nearly all of the risk. Assign it, schedule it, and record the verification date in the matrix.

Back to guide navigation

24

GoHealthcare Leadership Perspective

Coverage risk is a strategic input to service line decisions

When a musculoskeletal organization decides to add a device-based service line, the coverage landscape for that device category is as material an input as surgeon availability, capital cost, or case volume - and it is the one most often assessed last, informally, or not at all. Categories where commercial payers commonly apply investigational determinations will not generate the volume a proforma assumes, however clinically sound the service is.

The 2026 realignment changes the calculus for new technology

The direction of travel is toward faster coverage decisions for a narrower set of devices, with separate payment increasingly conditioned on demonstrated clinical improvement rather than regulatory designation. If the proposed repeal of the alternative pathway is finalized, the practical effect for an ASC is that fewer genuinely new implants will carry pass-through payment, and more will need to be absorbed within packaged procedure rates. That is a margin question, and it should be modeled before adoption rather than discovered after.

Early adoption carries an under-priced coverage cost

Adopting new device technology early has genuine clinical and competitive rationale. It also carries a cost that is rarely in the business case: an extended period of coverage uncertainty, imprecise coding, manual review, delayed cash, and denials that consume authorization and appeals capacity disproportionate to case volume. Leadership should price that period rather than assume it away.

Coverage advocacy is available and under-used

Provider organizations have more influence on coverage policy than they generally exercise. Public comment on proposed determinations, LCD reconsideration, commercial policy reconsideration, and specialty society engagement are all available. For a practice facing a recurring categorical denial, these address the cause rather than the instance, and the lowest-cost route for most organizations is coordinated engagement through the relevant professional society.

What leadership should require

• A device coverage matrix maintained separately from the procedure coverage matrix, with a named owner and a verification date on each entry.
• Coverage landscape assessment as a documented input to any device-based service line decision.
• Denial data distinguishing documentation-based from policy-based device denials.
• Margin modeling that accounts for the possibility that new technology will not carry separate payment.
• A defined patient financial counseling pathway for anticipated non-covered devices, with appropriate notice executed before the service.

• Monitoring assignment for the device categories the facility actually uses, and for the unresolved 2026 policy items identified in this guide.
• Governance visibility where a device category generates recurring denials, so the decision to continue or discontinue is made deliberately rather than by default.

Back to guide navigation

25

GoHealthcare Case Study

The following is an original composite educational scenario. It does not describe any actual patient, clinician, facility, organization, or device.

Scenario

A musculoskeletal practice with an affiliated ASC adopted a newly authorized implantable device for a peripheral nerve indication. The device had received FDA authorization, the manufacturer's clinical support was substantial, two surgeons had trained on it, and early clinical results were favorable. The practice projected meaningful volume. Nine months later the service line was discontinued with a substantial accumulated write-off.

Findings

• The practice had verified that the device was FDA authorized and concluded from that, without further inquiry, that coverage would follow.
• The device's authorized indication was narrower than the practice's clinical application. Roughly a third of cases fell outside it. Nobody had read the indications for use statement.
• No National Coverage Determination addressed the device. The applicable Medicare Administrative Contractor had no Local Coverage Determination either, leaving contractor discretion under the reasonable and necessary standard. Outcomes were inconsistent and unpredictable.
• Three of the practice's five largest commercial payers classified the device category as investigational. The practice had not checked before adopting, and had continued scheduling after the first denials on the assumption that appeals would succeed.
• The service carried a Category III CPT® code, which the practice had treated as a coding matter rather than a coverage signal.
• Appeals were filed on every denial, including the categorical investigational determinations. None of those succeeded. The appeals consumed a disproportionate share of the authorization team's capacity for two quarters.
• No Advance Beneficiary Notices had been issued, because non-coverage had not been anticipated. Medicare liability could not be transferred, and several patients received unexpected balances from commercial denials.

Analysis

The clinical judgment was sound and the device may well have been the right choice for these patients. Every failure was in coverage verification and financial process. The root cause was a single unexamined assumption - that FDA authorization implies coverage - compounded by the absence of any step in the pathway at which coverage was affirmatively verified before adoption.

The most damaging secondary failure was the appeals posture. By appealing categorical policy determinations as though they were documentation disputes, the practice spent two quarters of authorization capacity on claims that were never winnable, while denials that were winnable on documentation went unworked.

Resolution

• A device coverage verification step was inserted as a gate before any new device is adopted, requiring documented confirmation of FDA-authorized indication, Medicare coverage posture including contractor jurisdiction, and the position of each of the practice's major commercial payers.
• Authorized indications for use were obtained for every device system in regular use and recorded in a device reference maintained alongside the coverage matrix.
• Denial reasons were reclassified into documentation-based and policy-based categories, and the appeals policy was changed to stop pursuing categorical determinations at the case level.

• Policy-level remedies were pursued instead, through the relevant specialty society and through commercial policy reconsideration submissions supported by the practice's own outcome data.

• A patient financial counseling pathway was established for anticipated non-covered services, with notice execution before the service.
• Category III code assignment was added to the scheduling edit set as a coverage verification trigger.

Outcome

The device was reintroduced selectively for the subset of patients whose indication fell within both the FDA authorization and a payer coverage position, at substantially lower volume and positive margin. One commercial payer subsequently revised its position for a defined indication; the practice's reconsideration submission was one of several inputs. Authorization capacity previously consumed by unwinnable appeals was redirected. Leadership's stated lesson was that the verification gate would have cost a few hours before adoption and would have avoided nine months of loss.

Lessons learned

• FDA authorization is not coverage. This is the most expensive misconception in device operations.
• The authorized indication is frequently narrower than the clinical application, and nobody discovers this unless someone reads it.
• Absence of an NCD and an LCD is not permissive; it is unpredictable, and unpredictability is a planning problem.
• Commercial investigational determinations are policy positions. Appealing them at the case level consumes capacity and does not succeed.
• Category III codes are a coverage signal, not merely a coding detail.
• Anticipating non-coverage is a patient obligation as much as a financial control. Notice cannot be given retroactively.
• Coverage verification before adoption is cheap. Coverage discovery after adoption is not.

Back to guide navigation

26

GoHealthcare Best Practices

Domain	Practice
Adoption gate	No new device category is adopted without documented verification of FDA-authorized indication, Medicare coverage posture including contractor jurisdiction, and the position of each major commercial payer.
Device reference	Authorized indications for use retained for every device system in regular use, alongside the coverage matrix.
Coverage matrix	Device coverage matrix maintained separately from procedure coverage, recording policy number and version, covered indications, anatomic scope, prerequisites, exclusions, jurisdiction, contract basis, and verification date.
Criteria mapping	Each policy criterion mapped to supporting documentation before submission, with gaps closed rather than discovered.
Version monitoring	Policy version tracking for the device categories the facility actually uses, with a named owner and scheduled cadence.
Denial classification	Device denials classified as documentation-based or policy-based, with different response pathways for each.
Appeal discipline	Categorical policy determinations not appealed at the case level; policy-level remedies pursued instead.
Advocacy	Participation in public comment on proposed determinations and coordinated engagement through specialty societies where a category denies recurrently.
Study and CED compliance	Where coverage is conditioned on study or registry participation, enrollment documented pre-service and data submission obligations assigned.

Domain	Practice
Beneficiary notice	Anticipated non-coverage triggers advance notice and a patient financial conversation before the service, never after.
Coding vigilance	Category III and unlisted code assignment treated as coverage verification triggers; device code payability in the ASC setting confirmed.
Policy watch	The unresolved 2026 items - RAPID finalization, the pass-through alternative pathway repeal, and TCET's status - assigned to a named owner for monitoring.

Back to guide navigation

27

Common Mistakes

• Assuming FDA authorization means coverage. Separate agencies, separate standards, separate timelines.

• Never reading the indications for use statement. Authorized indications are frequently narrower than clinical reputation.
• Treating Breakthrough Device designation as a coverage status. It is a regulatory designation conferring eligibility for certain pathways, and CMS has proposed narrowing the payment advantages attached to it.
• Assuming a code means coverage. Code establishment is a payment mechanism and says nothing about whether a payer covers the device.
• Treating a Category III code as purely a coding matter. It is frequently the operative signal that coverage must be verified.
• Applying a national assumption where local coverage governs. Contractors differ, and multi-state organizations cannot maintain one Medicare matrix.
• Assuming Medicare coverage implies commercial coverage. Commercial policy is independent and diverges most for newer musculoskeletal categories.
• Appealing categorical investigational determinations at the case level. These are policy positions and consume capacity without succeeding.
• Failing to distinguish documentation denials from policy denials. They require entirely different responses.
• Assuming an investigational device exemption study means the device is covered. Coverage turns on the Category A or Category B determination.
• Treating Coverage with Evidence Development as an approval. It is coverage conditioned on study participation, and the condition must be satisfied and documented before the service.
• Issuing beneficiary notice after the service. Liability cannot be transferred retroactively.
• Verifying coverage once and carrying it forward. Policy versions change and devices move in and out of coverage.
• Assessing coverage landscape after a service line decision rather than as an input to it.
• Assuming graft, biologic, and enabling technology coverage follows the primary device. Each carries its own position.

Back to guide navigation

28

Pearls and Pitfalls

Pearls

• Obtain the indications for use statements once. It is a small effort that closes an entire denial category permanently.
• Build the submission to the policy's criteria, in the policy's order, using the policy's terminology. Reviewer time is the scarce resource.

• Cite the NCD or LCD by number and version, particularly for Medicare Advantage, where plans must apply Traditional Medicare criteria where they exist.

• Address exclusion criteria affirmatively rather than leaving them to be discovered.
• Measure and document trial response against the policy's stated threshold. For neuromodulation, this single element determines more outcomes than any other.

• Track denials by whether they are documentation-based or policy-based. This one classification changes how an entire appeals function operates.
• Comment on proposed coverage determinations. It is low-cost, genuinely influential, and almost never done by individual practices.

Pitfalls

• The absence of an NCD and an LCD is not permissive coverage; it is contractor discretion, which is unpredictable.
• Prior payment is not a coverage determination. Payment can occur in error and can stop without notice.
• The RAPID pathway is announced but not effective, and nothing in current practice should assume it.

• The pass-through alternative pathway repeal was proposed with final policies expected shortly after this guide's publication date. Verify the outcome.
• TCET is paused for new candidates, not repealed; organizations with pending applications should confirm their position directly.
• Coverage with Evidence Development conditions cannot be satisfied retroactively. Enrollment must precede the service.
• A device covered for one indication may be non-covered for another, and the distinction is frequently anatomic or level-specific rather than diagnostic.
• Humanitarian device exemption devices should not be assumed to carry coverage parity with cleared or approved devices.
• Commercial member liability rules for non-covered devices differ from Medicare and are constrained by contract terms and by federal and state balance billing protections.

Back to guide navigation

29

Frequently Asked Questions

Q1. Does FDA approval or clearance mean a device is covered?

No. FDA authorization establishes that a device may be lawfully marketed. Coverage is a separate determination made by Medicare or a commercial payer under a different standard. A device can be FDA-authorized, in routine clinical use, and non-covered by every payer a practice bills.

Q2. What is the difference between 510(k) clearance and premarket approval?

510(k) clearance establishes substantial equivalence to a legally marketed predicate device. Premarket approval establishes reasonable assurance of safety and effectiveness based on valid scientific evidence, for a specific approved indication. Payers frequently observe that substantial equivalence is not a demonstration of clinical benefit.

Q3. What is Breakthrough Device designation?

An FDA program under section 515B of the Federal Food, Drug, and Cosmetic Act for devices addressing life-threatening or irreversibly debilitating conditions that also meet at least one of four criteria: representing breakthrough technology, having no approved or cleared alternatives, offering significant advantages over existing alternatives, or availability being in patients' best interest. FDA decides designation requests within 60 calendar days. It is a regulatory designation, not a coverage decision.

Q4. What is the RAPID coverage pathway?

The Regulatory Alignment for Predictable and Immediate Device pathway, announced jointly by CMS and FDA on April 23, 2026, for certain Class II and Class III FDA-designated Breakthrough Devices. Eligibility requires participation in an investigational device exemption study that includes Medicare beneficiaries and agreed-upon clinical outcomes. CMS would issue a proposed National Coverage Determination the same day the device receives FDA market authorization.

Q5. Is RAPID in effect now?

No. As of this guide's publication date, RAPID has been announced but is not effective. A proposed procedural notice is to be published in the Federal Register with a 60-day comment period, and the pathway becomes effective upon publication of a final notice. Verify current status before relying on it.

Q6. Does RAPID mean automatic coverage when FDA authorizes a device?

No. RAPID synchronizes the start of the NCD process with FDA authorization rather than conferring coverage. The proposed NCD remains subject to public comment and CMS discretion. Coverage could become effective as soon as roughly two months after authorization, compared with approximately a year or more historically.

Q7. What happened to the TCET pathway?

CMS paused TCET for new candidates as it focuses on implementing RAPID. TCET was finalized in August 2024 for up to five Breakthrough Devices per year using the NCD and Coverage with Evidence Development processes. It is paused, not repealed; organizations with pending or planned applications should confirm their position with CMS directly.

Q8. What is the proposed repeal of the alternative pathway, and why does it matter to an ASC?

In the FY 2027 IPPS proposed rule published April 14, 2026, CMS proposed repealing the alternative pathway that permits Breakthrough Devices to qualify for New Technology Add-on Payment and outpatient device pass-through without demonstrating substantial clinical improvement. If finalized as proposed, OPPS device pass-through applications received on or after October 1, 2026 would need to demonstrate substantial clinical improvement. For an ASC this matters because pass-through is the mechanism by which a genuinely new implant is paid separately rather than absorbed into a packaged rate.

Q9. Is that repeal final?

Not as of this guide's publication date. Comments closed June 9, 2026 and final IPPS policies were expected on or around August 1, 2026, shortly after publication. Verify the outcome before relying on any statement in this guide about pass-through eligibility.

Q10. What is Coverage with Evidence Development?

A mechanism by which CMS covers an item or service only when it is furnished to a beneficiary participating in an approved clinical study or registry. It is used where evidence is promising but incomplete. The condition must be satisfied and documented before the service; it cannot be cured afterward.

Q11. What is the difference between a Category A and Category B investigational device?

Category A devices are experimental, where initial questions of safety and effectiveness remain unresolved; Medicare does not cover the device itself, though routine costs of care in a qualifying study may be covered. Category B devices are non-experimental or investigational, where the device type is known to be safe and effective or incremental risk is the principal question; these may be covered. Confirm the category before the case.

Q12. If no NCD or LCD addresses a device, is it covered?

Not automatically. Absence of policy means the determination falls to the contractor case by case under the reasonable and necessary standard. This is unpredictable rather than permissive, and it makes documentation quality determinative.

Q13. Can a device be covered in one state and not another under Medicare?

Yes. Local Coverage Determinations are contractor-specific, and different contractors may reach different conclusions on the same device. Multi-state organizations cannot maintain a single national Medicare coverage matrix.

Q14. If Medicare covers a device, must commercial payers?

No. Commercial coverage is independent and is determined by the plan's medical policy or its delegated vendor's criteria. Commercial plans regularly classify as investigational devices that Medicare covers, and divergence is widest for newer musculoskeletal device categories.

Q15. What about Medicare Advantage?

Medicare Advantage plans must apply Traditional Medicare coverage criteria where such criteria exist, and may apply internal criteria only where Traditional Medicare criteria are absent or incomplete. Citing the applicable NCD or LCD explicitly is the strongest available argument.

Q16. Does the existence of a HCPCS code mean the device is covered?

No. Code establishment is a payment and reporting mechanism. Coverage is a separate determination. This is among the most persistent misconceptions in device billing.

Q17. What does a Category III CPT® code signal?

That the service or technology is emerging. Category III codes are frequently associated with investigational determinations under payer policy. Treat assignment as a prompt to verify coverage before scheduling rather than as a coding detail.

Q18. What if a device is covered but has no specific code?

Report the applicable unclassified device code with documentation supporting the device furnished, and expect manual review. Prepare the supporting documentation in advance rather than in response to a request.

Q19. How should off-label use be handled?

Address it affirmatively in the authorization request, with clinical justification, supporting literature, and an explanation of why labeled alternatives are not appropriate for this patient. Silence on off-label use is a common denial basis, and the mismatch is frequently undetected because nobody read the indication.

Q20. Are humanitarian device exemption devices covered?

Coverage posture varies and is frequently restrictive. Do not assume parity with cleared or approved devices; verify the specific payer's position.

Q21. When is it worth appealing a device denial?

When the payer is saying the documentation is insufficient. When the payer is saying the device is not covered for anyone, that is a policy position, appeals rarely succeed, and the correct response is policy-level remedies, contract discussion, patient financial counseling, or declining to schedule against that payer.

Q22. What policy-level remedies exist?

LCD reconsideration requests to the Medicare Administrative Contractor; NCD reconsideration requests to CMS; public comment on proposed determinations and proposed rules; commercial policy reconsideration submissions; and coordinated advocacy through specialty societies, which is the most accessible route for most individual practices.

Q23. What documentation most often determines a neuromodulation device coverage outcome?

The trial documentation. Trial dates, duration, measured response against the policy's stated threshold, functional change, and medication change. A trial characterized as successful without measurement is the most consequential single gap in device coverage documentation.

Q24. Do we need a psychological evaluation?

Several neuromodulation policies require one before permanent implantation. Where required, it must be obtained and submitted, and it must precede the request. A common failure is an evaluation performed by an outside clinician that the authorization team never collects.

Q25. When must an Advance Beneficiary Notice be issued?

In advance of the service, where payment is expected to be denied as not reasonable and necessary. Financial liability cannot be transferred to a Medicare beneficiary retroactively. The GA modifier is then reported; GZ applies where the service is expected to be denied and no notice was issued, in which case liability cannot be transferred.

Q26. Do commercial plans have equivalent notice requirements?

They have their own advance notice and member liability rules, which differ from Medicare and from each other, and which are constrained by contract terms and by federal and state balance billing protections. Record them in the payer matrix alongside the coverage position.

Q27. How often should device coverage be re-verified?

Policy versions change on defined cycles and devices move in and out of coverage. Monitoring every device policy is impractical; monitoring the ten or fifteen categories a facility actually implants is practical and captures nearly all of the risk.

Q28. Should coverage landscape influence service line decisions?

Yes, and it should be a documented input rather than an afterthought. A device category subject to widespread commercial investigational determinations will not generate the volume a proforma assumes, however clinically sound the service is.

Q29. Does coverage of a fusion procedure cover the graft material?

No. Graft materials, biologics, and enabling technologies such as navigation and robotics each carry their own coverage positions, several of which are restrictive. Verify separately.

Q30. What is the single most valuable control in device coverage?

A verification gate before adoption. Documented confirmation of the FDA-authorized indication, the Medicare coverage posture including contractor jurisdiction, and the position of each major commercial payer, completed before the first case is scheduled. It costs hours; its absence costs quarters.

Back to guide navigation

30

Key Takeaways

• FDA authorization and coverage are separate determinations. This is the most expensive misconception in device operations and the source of most avoidable device loss.
• Authorized indications are frequently narrower than clinical reputation. Obtain and read the indications for use statement for every system in regular use.

• Breakthrough Device designation is a regulatory status, not a coverage status, and CMS has proposed narrowing the payment advantages historically attached to it.
• The RAPID pathway, announced April 23, 2026, would issue a proposed NCD the same day as FDA market authorization for eligible Breakthrough Devices. It is not yet effective and confers no automatic coverage.
• TCET is paused for new candidates. The standard NCD process, local coverage, and Coverage with Evidence Development remain operative.
• The proposed repeal of the alternative pathway would require device pass-through applicants to demonstrate substantial clinical improvement for applications received on or after October 1, 2026. Proposed, not final, with the outcome expected shortly after this guide's publication.
• Most musculoskeletal device coverage lives at the local contractor level, which means it varies by jurisdiction and cannot be maintained as a single national matrix.
• Commercial coverage is independent of Medicare and diverges most for the newest musculoskeletal device categories.
• Coverage with Evidence Development conditions and investigational device exemption categories must be confirmed and documented before the service; neither can be cured afterward.
• The existence of a code is not a coverage determination. Category III assignment is a coverage signal.
• Distinguish documentation denials from policy denials. They require entirely different responses, and appealing categorical determinations at the case level consumes capacity without succeeding.

• Anticipated non-coverage triggers a pre-service beneficiary notice and a patient financial conversation. Liability cannot be transferred retroactively.

Back to guide navigation

31

Future Outlook

Faster coverage for fewer devices

The 2026 realignment points toward compressed timelines for devices that qualify and tighter qualification criteria for separate payment. The net effect for an ASC is likely to be more new technology arriving already packaged into procedure rates, which raises the importance of implant margin modeling rather than lowering it.

Substantial clinical improvement returns as the operative criterion

If the alternative pathway repeal is finalized, demonstrated clinical improvement rather than regulatory designation becomes the gate for add-on and pass-through payment. This shifts advantage toward manufacturers who invest in comparative outcome evidence, and it will likely shift the composition of what reaches the ASC market.

Evidence generation moves earlier

Both RAPID and TCET reflect an intent to align evidence generation for regulatory review with evidence needs for coverage. If that alignment holds, coverage determinations may increasingly rest on evidence designed with the Medicare population in mind, which has historically been a significant gap.

Registry and real-world evidence become more consequential

Coverage with Evidence Development and fit-for-purpose study designs place weight on registries and data collected through care delivery. Facilities that can participate reliably in registries will have access to coverage pathways that facilities without that capability will not, and registry participation is likely to become a service line prerequisite in some categories.

Commercial divergence is unlikely to narrow

Nothing in the current architecture obliges commercial payers to follow accelerated Medicare coverage. Practices should expect the Medicare-commercial gap for new device technology to persist and possibly widen, and should verify commercial positions independently regardless of Medicare developments.

Coverage becomes a service line design input

As device technology proliferates faster than coverage policy adapts, coverage landscape assessment moves from a back-office verification task to a strategic input in service line planning. Organizations that build it into the decision will adopt more selectively and more profitably than those that verify after the fact.

Back to guide navigation

32

References

1. Centers for Medicare & Medicaid Services and U.S. Food and Drug Administration. CMS and FDA Announce RAPID Coverage Pathway to Accelerate Patient Access to Life-Changing Medical Devices, April 23, 2026. Website: https://www.cms.gov/newsroom/pre ss-releases/cms-fda-announce-rapid-coverage-pathway-accelerate-patient-access-life-changing-medical-devices

2. U.S. Food and Drug Administration. CMS and FDA Announce RAPID Coverage Pathway to Accelerate Patient Access to Life-Changing Medical Devices. Website: https://www.fda.gov/news-events/press-announcements/cms-and-fda-announce-rapid-cover age-pathway-accelerate-patient-access-life-changing-medical-devices

3. Federal Register. Medicare Program; Transitional Coverage for Emerging Technologies, final notice, August 12, 2024. Website: https: //www.federalregister.gov/documents/2024/08/12/2024-17603/medicare-program-transitional-coverage-for-emerging-technologies

4. Centers for Medicare & Medicaid Services. Transitional Coverage for Emerging Technologies (TCET) program page. Website: https://www.cms.gov/medicare/coverage/transitional-coverage-emerging-technologies

5. Federal Register. Medicare Program; Fiscal Year 2027 Hospital Inpatient Prospective Payment Systems proposed rule, 91 Fed. Reg. 19312, April 14, 2026, including the proposed repeal of the alternative pathway for New Technology Add-on Payment and outpatient device pass-through. Website: https://www.federalregister.gov

6. Centers for Medicare & Medicaid Services. Medicare Coverage Determination Process. Website: https://www.cms.gov/medicare/coverage/determination-process

7. Centers for Medicare & Medicaid Services. Medicare Coverage Database, containing National Coverage Determinations, Local Coverage Determinations, and Local Coverage Articles. Website: https://www.cms.gov/medicare-coverage-database/

8. Centers for Medicare & Medicaid Services. Coverage with Evidence Development. Website: https://www.cms.gov/medicare/coverage/evidence

9. Centers for Medicare & Medicaid Services. Medicare Coverage of Investigational Device Exemption (IDE) Studies. Website: https://www.cms.gov/medicare/coverage/investigational-device-exemption-ide-studies

10. Centers for Medicare & Medicaid Services. Medicare Program Integrity Manual, Publication 100-08, addressing local coverage determination development and reconsideration. Website: https://www.cms.gov/medicare/regulations-guidance/manuals/internet-only-manuals-ioms

11. Centers for Medicare & Medicaid Services. Medicare Claims Processing Manual, Publication 100-04, Chapter 30 (Financial Liability Protections), addressing Advance Beneficiary Notice and associated modifiers. Website: https://www.cms.gov/medicare/regulations-guidance/manuals/internet-only-manuals-ioms

12. Electronic Code of Federal Regulations. 42 CFR Part 405, Subpart B - Medical services coverage decisions that relate to health care technology, including investigational device categorization. Website: https://www.ecfr.gov/current/title-42/chapter-IV/subchapter-B/part-405/subpart-B

13. Electronic Code of Federal Regulations. 42 CFR 419.66 - Transitional pass-through payments: Medical devices. Website: https://www.ecfr.gov/current/title-42/chapter-IV/subchapter-B/part-419/subpart-G/section-419.66

14. Social Security Act, section 1862(a)(1)(A) - reasonable and necessary standard. Website: https://www.ssa.gov/OP_Home/ssact/title18/1862.htm

15. Federal Food, Drug, and Cosmetic Act, section 515B - Breakthrough Devices Program, 21 U.S.C. 360e-3. Website: https://uscode.house.gov

16. U.S. Food and Drug Administration. Breakthrough Devices Program guidance. Website: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/breakthrough-devices-program

17. U.S. Food and Drug Administration. Premarket Notification 510(k). Website: https://www.fda.gov/medical-devices/premarket-submis sions-selecting-and-preparing-correct-submission/premarket-notification-510k

18. U.S. Food and Drug Administration. Premarket Approval (PMA). Website: https://www.fda.gov/medical-devices/premarket-submissions-selecting-and-preparing-correct-submission/premarket-approval-pma

19. U.S. Food and Drug Administration. De Novo Classification Request. Website: https://www.fda.gov/medical-devices/premarket-sub missions-selecting-and-preparing-correct-submission/de-novo-classification-request

20. U.S. Food and Drug Administration. Humanitarian Device Exemption. Website: https://www.fda.gov/medical-devices/premarket-sub missions-selecting-and-preparing-correct-submission/humanitarian-device-exemption

21. U.S. Food and Drug Administration. Investigational Device Exemption (IDE). Website: https://www.fda.gov/medical-devices/premark et-submissions-selecting-and-preparing-correct-submission/investigational-device-exemption-ide

22. U.S. Food and Drug Administration. Device Classification Panels and Product Classification database. Website: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPCD/classification.cfm

23. U.S. Food and Drug Administration. Devices@FDA database. Website: https://www.accessdata.fda.gov/scripts/cdrh/devicesatfda/index.cfm

24. U.S. Food and Drug Administration. MAUDE - Manufacturer and User Facility Device Experience database. Website: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfmaude/search.cfm

25. U.S. Food and Drug Administration. Medical Device Recalls. Website: https://www.fda.gov/medical-devices/medical-device-safety/medical-device-recalls

26. eviCore healthcare. Clinical guidelines. Website: https://www.evicore.com/provider/clinical-guidelines

27. Carelon Medical Benefits Management. Clinical appropriateness guidelines. Website: https://guidelines.carelonmedicalbenefitsmanagement.com

28. Cohere Health. Provider resources. Website: https://coherehealth.com

29. Evolent. Provider resources. Website: https://www.evolent.com

30. TurningPoint Healthcare Solutions. Provider resources. Website: https://www.turningpoint-healthcare.com

31. UnitedHealthcare. Medical and drug policies and coverage determination guidelines. Website: https://www.uhcprovider.com

32. Aetna. Clinical Policy Bulletins. Website: https://www.aetna.com/health-care-professionals/clinical-policy-bulletins.html

33. Cigna Healthcare. Coverage policies. Website: https://static.cigna.com/assets/chcp/resourceLibrary/coveragePolicies/

34. Humana. Medical and pharmacy coverage policies. Website: https://www.humana.com/provider/medical-resources/clinical/coverage-policies

35. North American Spine Society. Coverage recommendations and clinical guidelines. Website: https://www.spine.org

36. American Academy of Orthopaedic Surgeons. Clinical practice guidelines. Website: https://www.aaos.org

37. International Neuromodulation Society. Website: https://www.neuromodulation.com

38. North American Neuromodulation Society. Website: https://www.neuromodulation.org

39. American Society of Interventional Pain Physicians. Website: https://www.asipp.org

40. American Medical Association. CPT® Current Procedural Terminology, including Category III codes. Website: https://www.ama-assn.org/practice-management/cpt

Back to guide navigation

33

Reading Recommendations

• The RAPID proposed procedural notice when it publishes in the Federal Register, and the subsequent final notice, which will determine whether and how the pathway operates.
• The FY 2027 IPPS final rule, expected on or around August 1, 2026, specifically for the disposition of the proposed alternative pathway repeal and its application to outpatient device pass-through.

• The TCET final notice of August 2024, which remains the most complete articulation of CMS thinking on evidence development for emerging device technology even while the pathway is paused.
• The Medicare Coverage Database, searched for each device category the facility uses, filtered to the facility's own contractor jurisdiction.

• The applicable Local Coverage Determinations and Local Coverage Articles in full, including the covered diagnosis lists, which is where most musculoskeletal device coverage actually resides.
• The FDA indications for use statement for every device system in regular use, obtained from Devices@FDA or the manufacturer's labeling.
• CMS guidance on Medicare coverage of investigational device exemption studies, for any facility participating in device trials.
• The device-relevant clinical policies of the facility's largest commercial payers, with attention to how each defines investigational and experimental.
• Comparative effectiveness literature for device categories the facility is considering adopting, with attention to comparator selection, follow-up duration, and whether the study population resembles the Medicare population.

Back to guide navigation

34

Related GoHealthcare Resources

Guide	Focus	Status
B04-01 - ASC Prior Authorization	The three concurrent Medicare prior authorization regimes, commercial site-of-service review, and facility versus professional authorization.	Published
B04-02 - ASC Documentation Requirements	Conditions for Coverage, medical record standards, and the 2019 history and physical policy change.	Published
B04-03 - Implant Authorization	Device-intensive payment, pass-through mechanics, device HCPCS reporting, credit modifiers, and implant margin.	Published
B04-04 - Medical Device Coverage	This guide.	Published
B04-05 - Same-Day Surgery Documentation	The perioperative record including device capture at the point of use.	Planned
B04-06 - Observation versus Outpatient	The 24-hour standard, extended recovery, and case selection.	Planned
B04-07 - Medicare ASC Billing	ASC payment system mechanics including device-intensive calculation.	Planned
B04-08 - Commercial ASC Billing	Contract structures, implant carve-outs, and balance billing protections.	Planned
B04-09 - Revenue Cycle for ASCs	Revenue cycle design, implant margin analytics, and denial management.	Planned
B04-10 - Compliance and Accreditation	Compliance program design, survey readiness, and quality reporting.	Planned

Device-specific coverage content appears in the procedure guides of the GoHealthcare MSK Specialty Procedure Library™, including the neuromodulation, lumbar spine surgical, and facet joint intervention series. Website: https://www.gohealthcarellc.com

Back to guide navigation

35

Recommended Downloads

• Device Adoption Verification Gate - the pre-adoption checklist covering FDA authorized indication, Medicare coverage posture by jurisdiction, and major commercial payer positions.
• Device Coverage Matrix template - policy number and version, covered indications, anatomic scope, prerequisites, exclusions, jurisdiction, contract basis, and verification date, by device category.

• Indications for Use Reference - a structured record of the FDA-authorized indication for every device system in regular use.
• Coverage Criteria Mapping worksheet - each policy criterion mapped to the documentation that satisfies it, with gap identification.
• Device Denial Classification Taxonomy - controlled vocabulary distinguishing documentation-based from policy-based denials, supporting differential response.
• Investigational Device Study Checklist - IDE category confirmation, study approval documentation, coverage conditions, and billing requirements.
• Coverage with Evidence Development Compliance form - enrollment verification, data submission responsibility assignment, and audit trail.
• Beneficiary Notice Decision Tree - when notice is required, which modifier pathway applies, and the pre-service timing obligation.
• Policy Version Monitoring Log - scheduled verification of coverage policy versions for the device categories in regular use.
• 2026 Policy Watch Tracker - RAPID finalization, the pass-through alternative pathway repeal disposition, and TCET status, with owner and review date.

Back to guide navigation

36

Visual Recommendations

Visual	Purpose	Placement
FDA-to-coverage gap diagram	The independent tracks of FDA authorization and payer coverage, with the historical interval and the RAPID compression shown.	Overview and Medicare Device Coverage sections.
FDA pathway comparison chart	510(k), premarket approval, De Novo, humanitarian device exemption, and investigational device exemption, with what each establishes and its coverage implication.	FDA Regulatory Pathways section.
Coverage pathway comparison matrix	Standard NCD, local coverage, Coverage with Evidence Development, TCET, and RAPID across status, scope, eligibility, and timing.	Coverage Pathway Comparison section.
Coverage verification decision tree	Branching logic from device identification through FDA indication, benefit category, national and local coverage, and commercial position.	Device Coverage Verification Workflow section.
Four-proposition medical necessity diagram	Condition warrants intervention, device-based intervention appropriate, category appropriate, specific device appropriate.	Medical Necessity for Devices section.
Category A versus Category B comparison	Investigational device exemption categories with their differing Medicare treatment.	Non-Coverage section.

Visual	Purpose	Placement
Denial classification matrix	Documentation-based versus policy-based denials, with the corresponding response pathway.	Appeals section.
Policy-level remedy map	LCD reconsideration, NCD reconsideration, public comment, commercial reconsideration, and society engagement, with effort and reach compared.	Appeals section.
Beneficiary notice decision tree	Notice requirement, timing obligation, and modifier selection.	Modifiers and Beneficiary Notice section.
2026 policy timeline	TCET finalization, RAPID announcement, the proposed repeal, comment deadlines, and expected final rule dates, with unresolved items marked.	Overview and Future Outlook sections.

Back to guide navigation

38

Educational Disclaimer

Educational Disclaimer, Limitations, and Terms of Use

This guide is provided for educational and operational reference purposes only. By reading, distributing, or relying on this document, you acknowledge and accept the terms set out in this section in their entirety. If you do not accept these terms, do not use this document.

1. Purpose and scope

This guide addresses the operational, documentation, coverage, medical necessity, prior authorization, utilization management, coding, and compliance considerations that surround the delivery of musculoskeletal specialty care. It is a practice operations resource. It is expressly not a clinical textbook, a procedural technique manual, a physician training guide, a specialty society practice guideline, a coding manual, a payer policy manual, or a legal treatise.

This guide does not provide, and must not be used as a source of, procedural or surgical technique, needle or instrument placement instruction, anesthesia technique, medication selection or dosing, imaging technique, device programming, or any other instruction bearing on the physical performance of a procedure on a patient.

2. No professional advice and no professional relationship

Nothing in this guide constitutes medical, nursing, legal, regulatory, compliance, accounting, tax, actuarial, coding, billing, reimbursement, or consulting advice. Reading or relying on this guide does not create a physician-patient relationship, a clinician-patient relationship, an attorney-client relationship, an accountant-client relationship, a consulting engagement, or any other professional, contractual, or fiduciary relationship with GoHealthcare Practice Solutions, with its officers, employees, or contractors, or with the author.

Readers should obtain advice from their own qualified clinical, legal, compliance, coding, and reimbursement professionals with respect to their specific facts, jurisdiction, payer contracts, and circumstances before acting on any information in this guide.

3. Independent clinical judgment governs all patient care

All decisions regarding patient evaluation, diagnosis, treatment selection, procedure selection, patient selection, anesthesia planning, site of service, and discharge are the exclusive responsibility of the treating licensed clinician exercising independent professional judgment for the individual patient. This guide does not, and cannot, account for any individual patient's clinical presentation, comorbidities, preferences, or circumstances. No content in this guide should be permitted to influence a clinical decision away from what the treating clinician judges to be in the patient's best interest.

4. Coverage, coding, and payment information is time-limited and may be superseded

National Coverage Determinations, Local Coverage Determinations, Local Coverage Articles, CMS manuals, transmittals, program instructions, demonstration and model parameters, commercial medical policies, utilization management vendor criteria, code sets, code descriptors, payment indicators, covered procedure lists, conversion factors, and quality reporting requirements all change frequently, are revised on differing cycles, may be applied differently by different contractors and jurisdictions, and may be amended, corrected, suspended, delayed, or withdrawn without notice.

All statements in this guide reflect publicly available authoritative sources as understood on the publication date stated in the Document History section. They may have been superseded by the time you read this. The reader is solely responsible for verifying every requirement against the primary source and the payer policy actually in effect on the applicable date of service. Where this guide and a primary source conflict, the primary source governs.

5. No guarantee of authorization, coverage, payment, or outcome

GoHealthcare Practice Solutions makes no representation, warranty, prediction, or guarantee that following any recommendation, checklist, template, workflow, or strategy described in this guide will result in prior authorization approval, affirmation, coverage, payment, reimbursement at any particular level, a successful appeal, avoidance of a peer-to-peer review, avoidance of audit or medical review, or any other outcome. Authorization is not a guarantee of payment. Payment is subject to eligibility, benefit design and limits, network status, coding accuracy, timely filing, medical necessity, contract terms, and all other applicable requirements.

6. Site-of-service and utilization content

This guide describes differences among care settings, including differences in coverage rules, prior authorization requirements, payment systems, and administrative burden. This descriptive content is provided so that operational teams can execute correctly in whichever setting the treating clinician selects.

It is not, and must not be construed as, guidance to select or steer a site of service, a procedure, a code, or a patient population for economic reasons, for the purpose of avoiding prior authorization or utilization review, or for any purpose other than the clinical appropriateness and safety of the individual patient. Site-of-service selection must be driven by clinical appropriateness, patient safety, and applicable regulatory and accreditation requirements. Patterns of setting, procedure, or coding selection that are not clinically grounded may implicate the Federal Anti-Kickback Statute, the physician self-referral law, the False Claims Act, the Civil Monetary Penalties Law, beneficiary inducement prohibitions, state corporate practice and fee-splitting laws, state insurance law, and payer contract terms. Readers should obtain legal counsel before adopting any practice that could be characterized as steering.

7. Compliance and program integrity remain the reader's responsibility

Nothing in this guide should be interpreted as encouraging, endorsing, or excusing the submission of any claim, code, modifier, diagnosis, or authorization request that is not fully supported by the contemporaneous medical record and by the service actually furnished. Documentation must reflect the care that was delivered. Coding must reflect the documentation. Any authorization request or claim submitted under a provider's identifier is that provider's representation, regardless of who prepared it and regardless of whether any template, tool, or automation was used in its preparation.

Each organization is solely responsible for its own compliance program, coding and billing accuracy, medical record integrity, licensure and accreditation obligations, privacy and security obligations, and adherence to all applicable federal, state, and local law and to all applicable payer contract terms.

8. Intellectual property and third-party content

• CPT® is a registered trademark of the American Medical Association. CPT® is copyright of the American Medical Association. All rights reserved. Any CPT® code references in this guide are provided for educational identification only and any descriptor language is paraphrased. This guide does not convey any license to use CPT® content. Users must obtain a license directly from the American Medical Association. Website: https://www.ama-assn.org
• HCPCS Level II codes and ICD-10-CM codes are maintained by the Centers for Medicare & Medicaid Services, the National Center for Health Statistics, and other responsible authorities. Code references are educational and are not a substitute for the official code sets and official coding guidelines.
• Commercial payer medical policies and utilization management vendor clinical criteria - including but not limited to those of eviCore, Carelon Medical Benefits Management, Cohere Health, Evolent, TurningPoint Healthcare Solutions, UnitedHealthcare, Aetna, Cigna Healthcare, Humana, Elevance Health, and Blue Cross Blue Shield licensees - are the proprietary property of their respective owners and may be subject to their own terms of use. This guide synthesizes and summarizes requirements at a general operational level and does not reproduce, republish, or substitute for those materials. Readers must consult the current policy or criteria document directly, under whatever license or terms of access apply to them.
• All other trademarks, service marks, product names, device names, and organization names referenced in this guide are the property of their respective owners and are used for identification purposes only.

9. No endorsement

References to any payer, health plan, utilization management vendor, device or implant manufacturer, accrediting organization, professional society, publication, product, service, or organization are for identification and educational purposes only. They do not constitute an endorsement, recommendation, certification, or warranty by GoHealthcare Practice Solutions, and they do not imply any affiliation, sponsorship, partnership, or relationship with, or approval by, any such entity.

10. Third-party websites and links

This guide includes website addresses for authoritative primary sources as a convenience. GoHealthcare Practice Solutions does not control those sites and is not responsible for their content, availability, accuracy, currency, or terms of use. Inclusion of an address does not constitute endorsement of the site or its operator. Addresses may change or cease to function after publication.

11. Case studies, examples, templates, and checklists

All case studies, scenarios, examples, and quantitative illustrations in this guide are original composite educational constructions. They do not describe, and are not derived from, any actual patient, clinician, facility, health plan, or organization. Any resemblance to an actual person or entity is unintended and coincidental. No protected health information is contained in this guide.

Any checklist, template, workflow, matrix, or framework offered in this guide is a starting point requiring adaptation to the reader's own setting, payer mix, contracts, state law, accreditation standards, and clinical program. It should be reviewed and approved by the reader's own clinical, compliance, and legal leadership before adoption.

12. Preparation, verification status, and known limitations

This guide was prepared using publicly available authoritative sources. It was prepared without live access to proprietary payer policy databases, licensed code set databases, claims adjudication systems, or subscription clinical criteria platforms. Notwithstanding the verification performed, the reader should assume the possibility of error, omission, ambiguity, or subsequent supersession, and should independently verify any point on which the reader intends to rely. The verification and review status of this specific guide is recorded in the Document History section and should be consulted before operational use.

13. No warranty

This guide is provided "as is" and "as available," without warranty of any kind, whether express, implied, or statutory, including without limitation any implied warranty of accuracy, completeness, currency, reliability, title, non-infringement, merchantability, or fitness for a particular purpose. GoHealthcare Practice Solutions does not warrant that the information in this guide is accurate, complete, current, or applicable to any particular circumstance.

14. Limitation of liability

To the fullest extent permitted by applicable law, neither GoHealthcare Practice Solutions nor its officers, directors, members, employees, contractors, agents, or the author shall be liable for any direct, indirect, incidental, consequential, special, exemplary, or punitive damages, or for any loss of revenue, profit, reimbursement, data, goodwill, or business opportunity, or for any claim denial, recoupment, penalty, sanction, audit finding, or regulatory action, arising out of or in connection with the use of, reliance on, or inability to use this guide, whether based in contract, tort, negligence, strict liability, or any other theory, and whether or not advised of the possibility of such damages.

15. Copyright and permitted use

© 2026 GoHealthcare Practice Solutions. All rights reserved. GoHealthcare MSK Specialty Procedure Library™ and the GoHealthcare Clinical Procedure Guide Standard™ are marks of GoHealthcare Practice Solutions. This guide may be read, printed, and shared internally within a healthcare organization for its own educational and operational purposes, provided it is reproduced in full, without alteration, and with all attribution and this disclaimer intact. It may not be resold, relabeled, incorporated into a commercial product or training program, or republished externally without prior written permission.

16. Corrections and feedback

GoHealthcare Practice Solutions welcomes correction. If you identify an error, an omission, or a superseded requirement in this guide, please contact us so that it can be evaluated and addressed in a subsequent version. Website: https://www.gohealthcarellc.com

In Short

Summary. Verify everything against the primary source and the payer policy in effect on the date of service. Let clinical judgment govern patient care and site of service. Document what was actually done. Obtain your own legal and compliance advice. This guide informs your process; it does not assume your risk.

GoHealthcare Practice Solutions is a national Musculoskeletal Specialty Management Services Organization supporting Pain Management, Orthopedic Surgery, Spine Surgery, Neurosurgery, Neuromodulation, and Ambulatory Surgery Centers. Website: https://www.gohealthcarellc.com

Back to guide navigation

Developed by

Pinky Maniri

MSc, BSc, CRCR, CSAPM, CSPPM, CSBI, CSPR, CSAF, Certified in Healthcare A.I. Governance

Founder and Chief Executive Officer, GoHealthcare Practice Solutions

LinkedInGoHealthcare

Strengthen ASC documentation, authorization, and revenue integrity.

GoHealthcare Practice Solutions helps musculoskeletal specialty organizations translate payer, regulatory, documentation, coding, and operational requirements into reliable workflows.

Request HelpExplore the Procedure Library